The people

Board

Michel Baijot

Independent chairman of the board

Michel Baijot, PhD, is a bioengineer with over 25 years of experience in building biologicals businesses, making a significant contribution to strategy, licensing, M&A and technology transfer, with in-depth knowledge of developed and emerging markets. He is currently Board Director of Radiomics, White Fund, Sinovac, 20 Med Therapeutics and Flash Therapeutics. His previous positions include Executive Director Europe at Serum Institute of India, Head of Cipla Global Vaccine, Chief Business Officer at Janssen/Crucell, Vice President Worldwide Strategic Alliances and Business Development at GlaxoSmithKline Biologicals and Vice President Business Development at Innogenetics. He was Chairman of the Belgian Biotech Association for five years.

Leen Limbourg

Representing Noshaq

Leen Limbourg earned an MD, and a degree in Public Health at Leuven University, and Strategic Health Economics from Stockholm School of Economics. She also obtained an MBA at Vlerick Business School.

She spent the first 10 years of her career in the pharmaceutical industry, in international medico-marketing roles. In the next decade, she supported biotech and MedTech companies as a consultant. She co-founded a HealthTech start-up, and learned what it takes to start a project from scratch. These experiences are crucial in her current job as an investor and board member: Leen is active in Europe in Biotech, MedTech, and SportsTech funds and got trained at INSEAD as a Board Chair.

Leen is passionate about exploring the boundaries of health, engineering, and technology where innovation is happening.

Bernard Surlemont

Representing Epimede

After ten years of experience in international business and INSEAD MBA and PhD in Strategic Management, Bernard Surlemont became professor of entrepreneurship at Liège University (Belgium) and Lausanne (Switzerland). In 1988, he launched the TTO of Liège University. He was co-founder of Mithra Pharmaceuticals, the VC Fund E-Capital I, Epimede. In 2004 he launched the first Belgian master in entrepreneurship at HEC-ULiège. He is board member of several start-ups and VCs funds. In 2000 he created SEED (now EKLO), an incubator to coach High-growth potential start-ups. He is the founder of VentureLab, an incubator dedicated to support the creation of start-ups by students (www.venturelab.be). His expertise relies in scientific entrepreneurship, universities spin-offs and in entrepreneurial finance.

Jörg Stein

Representing management

Jörg is an entrepreneurial executive with more than 20 years of experience in fundraising, strategy and business development, R&D, product management and sales in both start-up and multinational corporations in the medical device industry. He covered position as Long-term C-level manager, board member and consultant with a proven track record in business development, financing and profitable growth. Since 2015 is Managing Director at M&P Unternehmensberatung GmbH and interim-CFO at Portabiles HealthCare Technologies GmbH and CardiLnk GmbH.

Team

Wim Vos

Chief Executive Officer

Wim Vos is a distinguished researcher and visionary leader in medical imaging, specializing in pneumology and oncology. With executive experience at Fluidda and Radiomics, he has driven advancements in advanced image analysis for these fields.

At Fluidda, Wim served as Chief Technology Officer (CTO), leading innovative projects that utilized advanced imaging technologies to enhance respiratory disease diagnosis and treatment in pneumology. He later assumed the role of Chief Commercial Officer (CCO), successfully establishing Fluidda as a key player in pneumology through comprehensive commercial strategies.

As CEO of Radiomics for the past five years, Wim has revolutionised precision medicine by applying advanced image analysis techniques to oncology. Radiomics, under his leadership, has made significant strides in early treatment evaluation, treatment response prediction, and patient stratification.

Wim's expertise is demonstrated through his publications in reputable scientific journals and active participation in industry conferences. Widely regarded as an esteemed expert, he is sought after for his deep insights into advanced image analysis and its impact on pneumology and oncology. Wim's collaborative approach and effective communication skills have amplified his influence within the industry.

Beyond his research and executive roles, Wim is dedicated to fostering the growth of aspiring researchers in medical imaging. He actively engages in mentorship programs, educational initiatives, and scientific collaborations, promoting innovation and knowledge sharing in pneumology and oncology.

Wim Vos's exemplary leadership, research contributions, and dedication to leveraging medical imaging for improved patient care have solidified his position as a highly respected figure. He continues to shape the future of advanced image analysis, unlocking new possibilities for precision medicine and transforming disease diagnosis and treatment in pneumology and oncology.

Carlos Meca

Chief Commercial Officer

Carlos serves as Chief Commercial Officer for Radiomics. He is a physicist by training with over 15 years of commercial and marketing strategy experience in the Medical Device space. Carlos focus is to provide the strategic commercial backbone to Radiomics activities and to develop long-term commercial partnerships with key customer anchored in win-win development and commercialisation agreements.

After his PhD in Medical Imaging with the Commissariat à l'énergie atomique in Paris, Carlos completed a master’s in Management of Technology & Innovation at Paris Dauphine. As a business consultant, he has supported several biotech and medtech start-up companies in their early-stage business plan developments. Subsequently, as a strategy and pricing consultant, he worked with most leading Medical device companies creating pricing and commercial strategies, before leading Johnson & Johnson’s strategic contracting for the EMEA region. During his time at J&J, he was responsible for spearheading Value-based Healthcare Agreements, exploring new business models and leading local commercial activities.

With Spanish and Portuguese background, having lived and worked in several European countries and worked for customers across the globe, Carlos contributes to the multicultural environment of Radiomics.bio.

Jeroen Cant

Chief Technology Officer

Jeroen Cant holds an M.Sc. in Electrical Engineering from Leuven University and a PhD in Physics from Antwerp University. With over 20 years of experience in the medical device industry, Jeroen leads the research and development teams at Radiomics. His focus is on optimizing the full radiomics image analysis pipeline and ensuring the technology remains state-of-the-art. He also oversees IT and strategic partnerships in grants.

Before joining Radiomics, Jeroen held several key positions at Agfa Radiology Solutions, where he was responsible for developing advanced clinical applications in medical imaging, particularly for CT, MRI, and PET. He also earned a Baekeland PhD grant to conduct research on a novel bedside imaging device for intensive care, after which he became the head of the Agfa research group on AI and image processing in X-ray imaging. Jeroen is also a frequent invited speaker at radiology conferences on these topics.

In addition to his industry roles, Jeroen is an active member of the Fonds voor Wetenschappelijk Onderzoek (FWO), serving on panels for applied biomedical research and data sciences (AI).

Jeroen is driven by a passion for translating cutting-edge research into practical medical applications that lead to tangible improvements for patient outcomes around the world.

Mariaelena Occhipinti

Chief Medical Officer

Mariaelena serves as the Chief Medical Officer at Radiomics.bio. She is a radiologist with a subspecialty in Thoracic Imaging and expertise in quantitative imaging. The clinical validity of the results obtained from quantitative imaging, combined with the existing and the expected future clinical needs of the healthcare community, are the fulcrum of her work.

Her activity within the company is dedicated to the rigorous development and application of our innovative technology; ensuring the appropriate quality of the data, performance of the artificial intelligence algorithms, and to guarantee the medical safety of radiomics solutions and products.

She possesses extensive experience validating quantitative imaging software solutions in the clinical setting, through numerous collaborations with international partners. Notably, two research fellowships in the US at the Beth Israel Deaconess Medical Center (Boston, Massachusetts) and at the Mayo Clinic (Rochester, Minnesota). Mariaelena holds an MD PhD in Clinical Science & Pulmonology from the University of Florence.

Mathieu Delveaux

Chief Financial Officer

Mathieu Delveaux is a commercial engineer from the Solvay Business School (2002). He developed his financial expertise for 15 years in various environments. He started his career in external audit at Deloitte where he spent nearly 5 years on various assignments from SMEs to large international companies.

In 2007, he joined the IBA group,a leader in advanced radiotherapy and molecular imaging, as financial controller of the molecular imaging activities. During the 5 years spent within the IBA group, he actively participated in international strategic operations (financial, modeling, due diligence, negotiation, etc.), in business development activities (merger-acquisition, new products) while developing experience in planning, budgeting and control. In 2011, he joined the Sowalfin group where he spent around 2 years as a senior analyst working on the financing of innovative start-ups / spin-offs & SMEs.

In 2013, he started working as an independent CFO with various asssignments, particularly in the health / biotechnology sector: Cisbio Bio-Assays (France with subsidiaries in the United States and China), CHR Mons Hainaut, Bio-Sourcing , Elysia, ANMI,…. He joined the Radiomics team as CFO in August 2019.